Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study

Summary

Methamphetamine use disorder is a major public health concern in Australia and globally. GLP-1 medications such as semaglutide (e.g. Ozempic) are approved for diabetes and medication, and may potentially affect craving for other substances apart from food. We do not know if this will help people who use methamphetamine ('ice') to reduce their use. This study will treat people who use methamphetamine with weekly injections of semaglutide. It will provide data on if this is a potentially safe and practical treatment for this group of people.

Timeline

Start

2026-09

Primary completion

2027-01

Completion

2027-03

Drugs

Indications